Teen Cannabis Use Rose After California Legalization, New Kaiser Study Confirms

The research, led by Kaiser Permanente Division of Research scientist Kelly Young-Wolff, draws on one of the largest adolescent cannabis datasets ever assembled in the United States. By analyzing more than 1.3 million confidential well-child screenings from 2011 to 2024, the team built a uniquely granular picture of how teen cannabis use shifted in step with the state's evolving cannabis policy.

Inside the Kaiser Permanente Study

Young-Wolff's team examined 1.3 million pediatric well-child visits among Kaiser Permanente patients aged 13 to 17 in Northern California across a 13-year window. During those visits, adolescents completed a confidential screening questionnaire that included questions about substance use — a methodology that captures behavior anonymously and at scale, sidestepping many of the recall and stigma issues that complicate teen drug surveys.

The pre-legalization picture was clear. Past-year cannabis use among Kaiser Permanente teens had been falling steadily, dropping from 10.4% in 2011 to 6.8% in 2016 — the year California voters approved Proposition 64 to legalize recreational cannabis for adults 21 and older.

Then the trend reversed. By 2017, the rate had climbed to 8.1%. In 2018 — the first full year of legal adult-use sales in California — it reached 9.5%. The increase continued as the regulated market expanded, before pandemic disruptions in 2020 and 2021 pulled rates back down across virtually every adolescent substance category.

What the Researchers Think Drove the Increase

The most striking finding may be the timing. Adolescent cannabis use began to rise after Proposition 64 passed in November 2016, but before the first licensed dispensary opened on January 1, 2018. That sequence suggests the inflection point was not access — it was perception.

Young-Wolff and her co-authors argue that legalization shifted social norms first. As cannabis moved from prohibition into a regulated consumer category, teens may have viewed it as less risky and more socially acceptable. By the time storefronts began opening across the state, the cultural conversation around cannabis had already changed.

The researchers also point to a basket of co-occurring trends that reshaped the cannabis landscape during this window: increased product availability, falling retail prices as licensed supply scaled, and the explosion of vape pens, including high-potency and flavored options that proved especially popular with younger consumers. Each of those forces likely amplified the underlying shift in attitudes captured by the screening data.

How These Findings Fit With the Broader Research

The Kaiser study lands in a year already crowded with high-profile cannabis-and-youth research, and the findings do not all point the same direction. A separate Kaiser Permanente study published in JAMA Health Forum in February 2026 — also led by Young-Wolff — followed 463,396 adolescents through age 26 and found that past-year cannabis use during adolescence was associated with roughly double the risk of incident psychotic and bipolar disorders, along with elevated risk of depressive and anxiety disorders.

Other 2026 hospital-based studies have reported that rates of adolescent cannabis use disorder did not rise meaningfully in the years after legalization in some markets, suggesting that the relationship between legalization and clinically significant teen harm is more complicated than headlines often imply.

The April 17 study does not claim to resolve that broader debate. It documents a specific, measurable shift in self-reported past-year use among California teens during a defined policy window. Translating that shift into individual risk requires the kind of longitudinal mental health work the Young-Wolff team has been publishing in parallel.

What This Means for Cannabis Policy in 2026

The political stakes are unusually high. As of April 2026, 25 states plus the District of Columbia have legalized adult-use cannabis, and several more — including Pennsylvania, North Carolina, and Hawaii — are actively debating legalization or have governor-led campaigns underway. Opponents have pointed to Northern California-style data as evidence that legalization carries real costs for adolescents. Supporters counter that prohibition never kept cannabis out of teens' hands, and that regulated markets at least allow for tested products, age-gated retail, and tax-funded prevention programs.

The Kaiser findings are likely to be cited on both sides. For lawmakers crafting new legalization frameworks, the study makes a sharper argument for upfront investment in three areas: well-funded youth prevention programming that begins before any retail rollout, restrictions on flavored and high-potency vape products that disproportionately appeal to younger users, and funded research infrastructure to track public health metrics in close to real time rather than years after the fact.

California itself has already moved on several of these fronts, but the Kaiser data suggest that those interventions came late relative to the social-norm shifts that began the moment Proposition 64 passed.

Implications for Parents, Schools, and Pediatricians

For pediatricians and school health teams in legal states, the practical takeaway is the importance of early, repeated, nonjudgmental conversations about cannabis with adolescents. The Kaiser study found that the upward shift in use predated visible changes in retail availability — meaning families and clinicians cannot wait for a dispensary to open down the street to start the conversation.

For parents, the study underscores that messaging matters. The teens captured in the data appear to have updated their perception of cannabis well before any new product was within physical reach. Adults, including those who themselves consume cannabis legally, have a meaningful role to play in modeling that adult-use legalization does not equal universal endorsement, especially during the years when adolescent brains are still developing.

School health officials face a parallel challenge. Most district-level cannabis curricula in California were designed in the prohibition era and have only been incrementally updated since 2016. The Kaiser data argues for a more honest, harm-reduction-aware approach — one that acknowledges the legality of adult cannabis use, names the specific developmental risks of adolescent use without resorting to scare tactics, and equips students with the practical literacy they need to make informed decisions as soon as they turn 21.

How the Findings Will Travel Beyond California

Because California's adult-use market is the largest in the country and one of the longest-running, public health researchers and policymakers in newer-legal states routinely look to it as a leading indicator. The Kaiser cohort is large enough, the timeline long enough, and the screening methodology consistent enough that the April 17, 2026 study will become a foundational citation in legalization debates for years to come.

Expect to see it referenced in legislative hearings in Pennsylvania and Hawaii, in regulatory rulemaking around vape and edible product design in newly legal markets, and in the next round of CDC and SAMHSA youth substance use briefings. Whether the data is read as an argument for or against legalization will depend largely on which other findings — including pandemic-era declines, separate hospital cannabis use disorder studies, and Young-Wolff's own work on cannabis and adolescent psychiatric outcomes — get cited alongside it.

Key Takeaways

• A Kaiser Permanente study of 1.3 million teen pediatric visits, published April 17, 2026 in JAMA Network Open, found that past-year cannabis use among Northern California teens rose after Proposition 64 passed in 2016.
• Teen cannabis use had been declining (10.4% in 2011 to 6.8% in 2016) before legalization, then climbed to 8.1% in 2017 and 9.5% in 2018, before falling during the COVID-19 pandemic.
• The increase began before licensed retail sales started in January 2018, suggesting shifts in social norms — not access — drove the early uptick.
• Lead author Kelly Young-Wolff cited reduced perceived risk, increased availability, lower prices, and the rise of flavored vape products as contributing factors.
• The findings will weigh heavily on legalization debates underway in Pennsylvania, North Carolina, and other states still deliberating in 2026.

Explore cannabis news, find dispensaries, and join the community at Budpedia.